Full, persistent blockade of central neurokinin-1 (NK1) receptors may be a potential antidepressant mechanism. The selective NK1 antagonist orvepitant (GW823296) was used to test this hypothesis. A preliminary positron emission tomography study in eight male volunteers drove dose selection for two randomized six week studies in patients with major depressive disorder (MDD). Displacement of central [11C]GR205171 binding indicated that oral orvepitant doses of 30–60 mg/day provided >99% receptor occupancy for ≥24 h. Studies 733 and 833 randomized patients with MDD and 17-item Hamilton Depression Rating Scale (HAM-D)≥22 to double-blind treatment with orvepitant 30 mg/day, orvepitant 60 mg/day or placebo (1:1:1). Primary outcome measure was change from baseline in 17-item HAM-D total score at Week 6 analyzed using mixed models repeated measures. Study 733 (n=328) demonstrated efficacy on the primary endpoint (estimated drug-placebo differences of 30 mg: −2.41, 95% confidence interval (CI) (−4.50 to −0.31) p=0.0245; 60 mg: –2.86, 95% CI (−4.97 to −0.75) p=0.0082). Study 833 (n=345) did not show significance (estimated drug-placebo differences of 30 mg: −1.67, 95% CI (−3.73 to 0.39) p=0.1122; 60 mg: −0.76, 95% CI (−2.85 to 1.32) p=0.4713). The results support the hypothesis that full, long lasting blockade of central NK1 receptors may be an efficacious mechanism for the treatment of MDD.
AlperKSchwartzKAKoltsR. (2007) Seizure incidence in psychopharmacological clinical trials: An analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry62: 345–354.
2.
BergrsömMFasthKJKilpatrickG. (2000) Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1- antagonists, GR203040 and GR205171—PET studies in rhesus monkey. Neuropharmacology39: 664–670.
3.
CarlettiRGriffanteCPozzatoC. (2005) NK1 receptor occupancy and anxiolytic-like effect of the novel NK1 receptor antagonist Vestipitant (GW597599) in gerbil. Eur Neuropsychopharmacol15(S3): S539.
4.
ChappellP (2002) Effects of CP-122,721, a selective NK-1 receptor antagonist, in patients with MDD. Presented at NCDEU June 12 2002, referenced in McLean S (2005): Do substance P and the NK1 receptor have a role in depression and anxiety?Curr Pharm Des11: 1529–1154.
5.
De FelipeCHerreroJFO’BrienJA. (1998) Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature392: 394–397.
6.
Di FabioRAlvaroGGriffanteC. (2011) Discovery and biological characterization of (2R,4S)-1‘-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4’-bipiperidine-1-carboxamide (Casopitant) as a new potent and selective NK1 receptor antagonist clinical candidate. J Med Chem54: 1071–1079.
7.
FavaM (2004) Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry65: S27–S32.
8.
FavaM (2006) Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry67: S14–S21.
9.
FavaMIosifescuDVPedrelliP. (2009) Reliability and validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire. Psychother Psychosom78: 91–97.
10.
FavaMRankinMAAlpertJE. (1998) An open trial of oral sildenafil in antidepressant-induced sexual dysfunction. Psychother Psychosom67: 328–331.
11.
FirstMBSpitzerRLGibbonM. (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York: Biometics Research, New York State Psychiatric Institute.
12.
GobbiGBlierP (2005) Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs. Peptides26:1383–1393.
HargreavesR (2002) Imaging substance P receptors (NK1) receptors in the living human brain using positron emission tomography. J Clin Psychiatry63: S18–S24.
17.
HesdorfferDCHauserWAOlafssonE. (2006) Depression and suicide attempt as risk factors for incident unprovoked seizures. Ann Neurol59: 35–41.
18.
InnisRBCunninghamVJDelforgeJ. (2006) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab27: 1533–1539.
19.
KalinichevMBradfordABisonS. (2010) Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the rat. Epilepsia51: 1543–1551.
20.
KellerMMontgomerySBallW. (2006) Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry59: 216–223.
21.
KhanAJCutlerAJKajdaszDK. (2011) A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry72: 441–447.
22.
KhinNAChenY-FYangY. (2011) Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry72: 464–472.
23.
KramerMSCutlerNFeighnerJ. (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science281: 1640–1645.
24.
KramerMSWinokurAKelseyJ. (2004) Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology29: 385–392.
25.
LabbateLALareSB (2001) Sexual dysfunction in male psychiatric outpatients: Validity of the Massachusetts General Hospital Sexual Functioning Questionnaire. Psychother Psychosom70: 221–225.
26.
LiXFryeMASheltonRC (2012) Review of pharmacological treatments in mood disorders and future directions for drug development. Neuropsychopharmacology37: 77–101.
27.
LiuHCaoYBasbaumAI. (1999a) Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. Proc Natl Acad Sci U S A96: 12096–12101.
28.
LiuHMazaratiAMKatsumoriH. (1999b) Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus. Proc Natl Acad Sci U S A96: 5286–5291.
29.
LuthraSKOsmanSTurtonDR. (1993) An automated system based on solid phase extraction and HPLC for the routine determination in plasma of unchanged [11C]-L-deprenyl; [11C]diprenorphine; [11C]flumazenil; [11C]raclopride; and [11C]Scherring-23390. J Labelled Comp Radiopharm32: 518–520.
30.
PosnerKBrownGKStanleyB. (2011) The Columbia Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry168: 1266–1277.
31.
RattiEBellewKBetticaP. (2011) Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol31: 727–733.
32.
RickelsKAthanasiouMRobinsonDS.(2009) Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry70: 326–333.
33.
RobinsonPGarzaAWeinstockJ. (2012) Substance P causes seizures in neurocysticercosis. PLoS Pathog8: e1002489.
34.
RoehrsTLamphereJPaxtonC. (1984) Temazepam’s efficacy in patients with sleep onset insomnia. Br J Clin Pharmacol17: 691–696.
35.
RushAJTrivediMHWisniewskiSR. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry163: 1905–1917.
36.
RushAJTrivediMHIbrahimHM. (2003) The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry54: 573–583.
37.
SantarelliLGobbiGDebsPC. (2001) Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci U S A98: 1912–1917.
38.
SpinksTJJonesTBloomfieldPM. (2000) Physical characteristics of the ECAT EXACT3D positron tomograph. Phys Med Biol45: 2601–2618.
39.
TargumSDPollackMHFavaM (2008) Redefining affective disorders: relevance for drug development. CNS Neurosci Ther14: 2–9.
40.
WilliamsJB (1988) A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry45: 742–747.
41.
ZachrissonOLindeforsNBrenéS (1998) A tachykinin NK1 receptor antagonist, CP-122,721-1, attenuates kainic acid-induced seizure activity. Brain Res Mol Brain Res60: 291–295.
42.
ZamunerSRabinerEAFernandesSA. (2012) A pharmacokinetic PET study of NK1 receptor occupancy. Eur J Nucl Med Mol Imaging39: 226–235.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
